Comment on "p38 MAPK inhibition alleviates experimental acute pancreatitis in mice"

作     者：Moulay Alaoui-Jamali 

作者机构：Mc Gill University Depart. Medicine and Oncology Lady Davis Institute for Medical ResearchSegal Cancer Centre 3755Chemin Cote Ste-Catherine Montreal Quebec H3T 1E2 CanadaProfessor 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2015年第14卷第3期

页      面：330-330页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：MAPK p38 MAPK inhibition alleviates experimental acute pancreatitis in mice Comment on 

摘      要：To the Editor：I read with great interest the article by Cao et al[1] re- porting a potential therapeutic utility of p38 inhibitors for acute pancreatitis. Using a preclinical mouse model where acute pancreatitis was induced by administra- tion of cerulein （a cholecystokinin analog derived from the tree frog Litoria caerulea）, the authors reported that the p38 MAPK inhibitor SB203580, administered intra- peritoneally before and after the first administration of cerulein, relieved signs associated with acute pancreatitis, including decreased HSP60 and HSP70 expression, and serum IL-6, amylase and lipase activities. Although the study remains descriptive and pharmacodynamic aspects were not examined in depth, it still has a merit as it undoubtedly provides a basis for further investigation into the potential utility of targeting p38 signaling for acute pancreatitis, a common serious condition that can be life-threatening.